Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Diabetes

  Free Subscription


Articles published in N Engl J Med

Retrieve available abstracts of 93 articles:
HTML format
Text format



Single Articles


    November 2017
  1. THORNTON SN, Regnault V, Lacolley P
    Liraglutide and Renal Outcomes in Type 2 Diabetes.
    N Engl J Med. 2017;377:2196-7.
    PubMed     Text format    


  2. IMPRIALOS KP, Stavropoulos K, Doumas M
    Liraglutide and Renal Outcomes in Type 2 Diabetes.
    N Engl J Med. 2017;377:2196.
    PubMed     Text format    


  3. GULLI G
    Liraglutide and Renal Outcomes in Type 2 Diabetes.
    N Engl J Med. 2017;377:2195-6.
    PubMed     Text format    


  4. TONNEIJCK L, van Raalte DH, Muskiet MHA
    Liraglutide and Renal Outcomes in Type 2 Diabetes.
    N Engl J Med. 2017;377:2195.
    PubMed     Text format    



  5. Liraglutide and Renal Outcomes in Type 2 Diabetes.
    N Engl J Med. 2017;377:2195-2199.
    PubMed     Text format    


  6. DE BOER IH
    Liraglutide and Renal Outcomes in Type 2 Diabetes.
    N Engl J Med. 2017;377:2198.
    PubMed     Text format    



  7. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
    N Engl J Med. 2017;377:2097-2099.
    PubMed     Text format    


  8. RAJAGOPALAN S, Brook R
    Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
    N Engl J Med. 2017;377:2098-9.
    PubMed     Text format    


  9. FERNANDEZBALSELLS MM, Sojo-Vega L, Ricart-Engel W
    Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
    N Engl J Med. 2017;377:2098.
    PubMed     Text format    


  10. BAGLIONI P
    Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
    N Engl J Med. 2017;377:2097-8.
    PubMed     Text format    


  11. PERFETTI R
    Safety of Degludec versus Glargine in Type 2 Diabetes.
    N Engl J Med. 2017;377:1995.
    PubMed     Text format    


  12. TAYEK JA, Danese PNN, Smith MS
    Safety of Degludec versus Glargine in Type 2 Diabetes.
    N Engl J Med. 2017;377:1994-5.
    PubMed     Text format    


  13. OGUNSAKIN AA, Jain N, Dagogo-Jack S
    Safety of Degludec versus Glargine in Type 2 Diabetes.
    N Engl J Med. 2017;377:1994.
    PubMed     Text format    



  14. Safety of Degludec versus Glargine in Type 2 Diabetes.
    N Engl J Med. 2017;377:1995-1996.
    PubMed     Text format    


  15. MARCOVECCHIO ML, Chiesa ST, Bond S, Daneman D, et al
    ACE Inhibitors and Statins in Adolescents with Type 1 Diabetes.
    N Engl J Med. 2017;377:1733-1745.
    PubMed     Text format     Abstract available


    October 2017
  16. MATSUO T, Ishii N
    Acute Esophageal Necrosis.
    N Engl J Med. 2017;377:1378.
    PubMed     Text format    


    September 2017
  17. ADAMS TD, Davidson LE, Litwin SE, Kim J, et al
    Weight and Metabolic Outcomes 12 Years after Gastric Bypass.
    N Engl J Med. 2017;377:1143-1155.
    PubMed     Text format     Abstract available


  18. HOLMAN RR, Bethel MA, Mentz RJ, Thompson VP, et al
    Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
    N Engl J Med. 2017 Sep 14. doi: 10.1056/NEJMoa1612917.
    PubMed     Text format     Abstract available


  19. GARG SK, Henry RR, Banks P, Buse JB, et al
    Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes.
    N Engl J Med. 2017 Sep 13. doi: 10.1056/NEJMoa1708337.
    PubMed     Text format     Abstract available


  20. NATHAN DM
    Adjunctive Treatments for Type 1 Diabetes.
    N Engl J Med. 2017 Sep 13. doi: 10.1056/NEJMe1711296.
    PubMed     Text format    


    August 2017
  21. DE BOER IH
    A New Chapter for Diabetic Kidney Disease.
    N Engl J Med. 2017;377:885-887.
    PubMed     Text format    


  22. MANN JFE, Orsted DD, Brown-Frandsen K, Marso SP, et al
    Liraglutide and Renal Outcomes in Type 2 Diabetes.
    N Engl J Med. 2017;377:839-848.
    PubMed     Text format     Abstract available


  23. VERMA R
    Insulin-Mediated Lipohypertrophy.
    N Engl J Med. 2017;377:573.
    PubMed     Text format    


    July 2017
  24. HALLER M, Atkinson M, Schatz D
    More on Intralymphatic Injection of Autoantigen in Type 1 Diabetes.
    N Engl J Med. 2017;377:403.
    PubMed     Text format    



  25. Intralymphatic Injection of Autoantigen in Type 1 Diabetes.
    N Engl J Med. 2017;377:405.
    PubMed     Text format    



  26. More on Intralymphatic Injection of Autoantigen in Type 1 Diabetes.
    N Engl J Med. 2017;377:403-5.
    PubMed     Text format    



  27. Incidence Trends of Type 1 and Type 2 Diabetes among Youths, 2002-2012.
    N Engl J Med. 2017;377:301.
    PubMed     Text format    


  28. MARTINEZ-CERON E, Garcia-Rio F
    Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes.
    N Engl J Med. 2017;377:300.
    PubMed     Text format    



  29. Incidence Trends of Type 1 and Type 2 Diabetes among Youths, 2002-2012.
    N Engl J Med. 2017;377:301.
    PubMed     Text format    



  30. Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes.
    N Engl J Med. 2017;377:300-301.
    PubMed     Text format    


  31. NATHAN DM, Bebu I, Lachin JM
    Frequency of Evidence-Based Screening for Diabetic Retinopathy.
    N Engl J Med. 2017;377:195.
    PubMed     Text format    



  32. Frequency of Evidence-Based Screening for Diabetic Retinopathy.
    N Engl J Med. 2017;377:194-195.
    PubMed     Text format    


  33. JANI SM, Nallamothu BK, Cooper LT, Smith A, et al
    Beating, Fast and Slow.
    N Engl J Med. 2017;377:72-78.
    PubMed     Text format    


    June 2017
  34. ARMSTRONG DG, Boulton AJM, Bus SA
    Diabetic Foot Ulcers and Their Recurrence.
    N Engl J Med. 2017;376:2367-2375.
    PubMed     Text format    


  35. NEAL B, Perkovic V, Mahaffey KW, de Zeeuw D, et al
    Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
    N Engl J Med. 2017 Jun 12. doi: 10.1056/NEJMoa1611925.
    PubMed     Text format     Abstract available


  36. MARSO SP, McGuire DK, Zinman B, Poulter NR, et al
    Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes.
    N Engl J Med. 2017 Jun 12. doi: 10.1056/NEJMoa1615692.
    PubMed     Text format     Abstract available


  37. FRALICK M, Schneeweiss S, Patorno E
    Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor.
    N Engl J Med. 2017;376:2300-2302.
    PubMed     Text format    


    May 2017
  38. ANKER MS, von Haehling S, Anker SD
    Bariatric Surgery or Intensive Medical Therapy for Diabetes after 5 Years.
    N Engl J Med. 2017;376:1996-7.
    PubMed     Text format    


  39. SCHAUER PR, Bhatt DL, Kashyap SR
    Bariatric Surgery or Intensive Medical Therapy for Diabetes after 5 Years.
    N Engl J Med. 2017;376:1997.
    PubMed     Text format    


  40. HOWARD DL
    Bariatric Surgery or Intensive Medical Therapy for Diabetes after 5 Years.
    N Engl J Med. 2017;376:1996.
    PubMed     Text format    


  41. SHUKLA AP, Aronne LJ
    Bariatric Surgery or Intensive Medical Therapy for Diabetes after 5 Years.
    N Engl J Med. 2017;376:1995-6.
    PubMed     Text format    


  42. LINCOFF AM, Nicholls SJ, Riesmeyer JS, Barter PJ, et al
    Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease.
    N Engl J Med. 2017;376:1933-1942.
    PubMed     Text format     Abstract available


  43. BAIDAL DA, Ricordi C, Berman DM, Alvarez A, et al
    Bioengineering of an Intraabdominal Endocrine Pancreas.
    N Engl J Med. 2017;376:1887-1889.
    PubMed     Text format    


  44. SMITH TJ, Kahaly GJ, Ezra DG, Fleming JC, et al
    Teprotumumab for Thyroid-Associated Ophthalmopathy.
    N Engl J Med. 2017;376:1748-1761.
    PubMed     Text format     Abstract available


  45. RAMSEY BW, Nepom GT, Lonial S
    Academic, Foundation, and Industry Collaboration in Finding New Therapies.
    N Engl J Med. 2017;376:1762-1769.
    PubMed     Text format    


    April 2017

  46. Frequency of Evidence-Based Screening for Retinopathy in Type 1 Diabetes.
    N Engl J Med. 2017;376:1507-1516.
    PubMed     Text format     Abstract available


  47. ROSENBERG JB, Tsui I
    Screening for Diabetic Retinopathy.
    N Engl J Med. 2017;376:1587-1588.
    PubMed     Text format    


  48. MAYER-DAVIS EJ, Lawrence JM, Dabelea D, Divers J, et al
    Incidence Trends of Type 1 and Type 2 Diabetes among Youths, 2002-2012.
    N Engl J Med. 2017;376:1419-1429.
    PubMed     Text format     Abstract available


  49. RAWSHANI A, Rawshani A, Franzen S, Eliasson B, et al
    Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes.
    N Engl J Med. 2017;376:1407-1418.
    PubMed     Text format     Abstract available


  50. INGELFINGER JR, Jarcho JA
    Increase in the Incidence of Diabetes and Its Implications.
    N Engl J Med. 2017;376:1473-1474.
    PubMed     Text format    


  51. LAVERY K, Gilden DJ, Saint S, Judson MA, et al
    A Bare-Bones Approach.
    N Engl J Med. 2017;376:1371-1376.
    PubMed     Text format    


    March 2017
  52. HUANG CS
    Fournier's Gangrene.
    N Engl J Med. 2017;376:1158.
    PubMed     Text format    


  53. IPP E, Genter P, Childress K
    Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
    N Engl J Med. 2017;376:890-1.
    PubMed     Text format    



  54. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
    N Engl J Med. 2017;379:890-1.
    PubMed     Text format    


  55. COSMI F, Laini R, Nicolucci A
    Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
    N Engl J Med. 2017;376:890.
    PubMed     Text format    


  56. WILLIAMS TC, Stewart E
    Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
    N Engl J Med. 2017;376:891.
    PubMed     Text format    



  57. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
    N Engl J Med. 2017;376:891-2.
    PubMed     Text format    


    February 2017
  58. LUDVIGSSON J, Wahlberg J, Casas R
    Intralymphatic Injection of Autoantigen in Type 1 Diabetes.
    N Engl J Med. 2017;376:697-699.
    PubMed     Text format    


  59. SCHAUER PR, Bhatt DL, Kirwan JP, Wolski K, et al
    Bariatric Surgery versus Intensive Medical Therapy for Diabetes - 5-Year Outcomes.
    N Engl J Med. 2017;376:641-651.
    PubMed     Text format     Abstract available


    December 2016
  60. MORAN-THOMAS A
    Breakthroughs for Whom? Global Diabetes Care and Equitable Design.
    N Engl J Med. 2016;375:2317-2319.
    PubMed     Text format    


  61. FERENCE BA, Robinson JG, Brook RD, Catapano AL, et al
    Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes.
    N Engl J Med. 2016;375:2144-2153.
    PubMed     Text format     Abstract available


    November 2016
  62. ANDERS HJ, Davis JM, Thurau K
    Nephron Protection in Diabetic Kidney Disease.
    N Engl J Med. 2016;375:2096-2098.
    PubMed     Text format    


  63. ALEGRE-DIAZ J, Herrington W, Lopez-Cervantes M, Gnatiuc L, et al
    Diabetes and Cause-Specific Mortality in Mexico City.
    N Engl J Med. 2016;375:1961-1971.
    PubMed     Text format     Abstract available


  64. GORDON CE, Vantzelfde S, Francis JM
    Acetazolamide in Lithium-Induced Nephrogenic Diabetes Insipidus.
    N Engl J Med. 2016;375:2008-2009.
    PubMed     Text format    


  65. PAREEK A, Chandurkar N, Naidu K
    Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
    N Engl J Med. 2016;375:1800.
    PubMed     Text format    


  66. WAKISAKA M
    Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
    N Engl J Med. 2016;375:1799-1800.
    PubMed     Text format    



  67. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
    N Engl J Med. 2016;375:1799-1802.
    PubMed     Text format    


  68. CORREIA LC, Latado A, Porzsolt F
    Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
    N Engl J Med. 2016;375:1798.
    PubMed     Text format    


  69. COHEN S, Beckey C
    Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
    N Engl J Med. 2016;375:1797.
    PubMed     Text format    



  70. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
    N Engl J Med. 2016;375:1797-1799.
    PubMed     Text format    


  71. PARVING H-H, Lambers-Heerspink H, de Zeeuw D
    Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
    N Engl J Med. 2016;375:1800-1.
    PubMed     Text format    


  72. ALVAREZ-VILLALOBOS NA, Trevino-Alvarez AM, Gonzalez-Gonzalez JG
    Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
    N Engl J Med. 2016;375:1797-8.
    PubMed     Text format    


    October 2016
  73. HIROSE Y, Kaida H
    Emphysematous Pyelonephritis.
    N Engl J Med. 2016;375:1671.
    PubMed     Text format    


  74. MACDONALD SM, Rapalino O, Sherry NA, Cohen AB, et al
    Case 32-2016. A 20-Year-Old Man with Gynecomastia.
    N Engl J Med. 2016;375:1567-1579.
    PubMed     Text format    


  75. BYRNE TN, Stone JH, Pillai SS, Rapalino O, et al
    Case Records of the Massachusetts General Hospital. Case 31-2016. A 53-Year-Old Man with Diplopia, Polydipsia, and Polyuria.
    N Engl J Med. 2016;375:1469-1480.
    PubMed     Text format    



  76. Diabetic Sensory and Motor Neuropathy.
    N Engl J Med. 2016;375:1402.
    PubMed     Text format    


    September 2016
  77. MARSO SP, Bain SC, Consoli A, Eliaschewitz FG, et al
    Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
    N Engl J Med. 2016.
    PubMed     Text format     Abstract available


  78. PERSAUD SJ, Jones PM
    A Wake-up Call for Type 2 Diabetes?
    N Engl J Med. 2016;375:1090-2.
    PubMed     Text format    


  79. RAN M, Wang Y
    Generalized Granuloma Annulare Associated with Diabetes Mellitus.
    N Engl J Med. 2016;375:e21.
    PubMed     Text format    


  80. ZHANG L, Long J, Jiang W, Shi Y, et al
    Trends in Chronic Kidney Disease in China.
    N Engl J Med. 2016;375:905-6.
    PubMed     Text format    


  81. WANG HS, Shih MC
    Emphysematous Prostatitis.
    N Engl J Med. 2016;375:879.
    PubMed     Text format    


    August 2016
  82. STEWART ZA, Wilinska ME, Hartnell S, Temple RC, et al
    Closed-Loop Insulin Delivery during Pregnancy in Women with Type 1 Diabetes.
    N Engl J Med. 2016;375:644-54.
    PubMed     Text format     Abstract available


    July 2016

  83. Paclitaxel-Eluting versus Everolimus-Eluting Coronary Stents in Diabetes.
    N Engl J Med. 2016;375:398.
    PubMed     Text format     Abstract available


    June 2016
  84. MUSTAFA OM, Aduriz-Lorenzo PM
    IMAGES IN CLINICAL MEDICINE. Hypopyon and Klebsiella Sepsis.
    N Engl J Med. 2016;374:e33.
    PubMed     Text format    


  85. SAHIN M, Corapcioglu D
    Metformin versus Placebo in Obese Pregnant Women without Diabetes.
    N Engl J Med. 2016;374:2501-2.
    PubMed     Text format     Abstract available


  86. STANFORD FC, Alfaris N, Misra M
    Metformin versus Placebo in Obese Pregnant Women without Diabetes.
    N Engl J Med. 2016;374:2501-2.
    PubMed     Text format     Abstract available



  87. Metformin versus Placebo in Obese Pregnant Women without Diabetes.
    N Engl J Med. 2016;374:2501-2.
    PubMed     Text format     Abstract available


  88. WANNER C, Inzucchi SE, Lachin JM, Fitchett D, et al
    Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
    N Engl J Med. 2016.
    PubMed     Text format     Abstract available


  89. INGELFINGER JR, Rosen CJ
    Cardiac and Renovascular Complications in Type 2 Diabetes - Is There Hope?
    N Engl J Med. 2016.
    PubMed     Text format     Abstract available


  90. MARSO SP, Daniels GH, Brown-Frandsen K, Kristensen P, et al
    Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
    N Engl J Med. 2016.
    PubMed     Text format     Abstract available


    May 2016
  91. BAYRY J
    Repressing Immunity in Autoimmune Disease.
    N Engl J Med. 2016;374:2090-2.
    PubMed     Text format    


  92. KHONSARI RH, Ruhin B
    IMAGES IN CLINICAL MEDICINE. Loose Teeth and Excessive Thirst.
    N Engl J Med. 2016;374:e25.
    PubMed     Text format    


  93. ALEXANDER JH, Smith PK
    Coronary-Artery Bypass Grafting.
    N Engl J Med. 2016;374:1954-64.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Diabetes is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: